Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease

• Published in: Oxidative medicine and cellular longevity 2021, Vol.2021 (1), p.5577541-5577541
• Main Authors: Jiménez-Delgado, Alicia, Ortiz, Genaro Gabriel, Delgado-Lara, Daniela L., González-Usigli, Hector Alberto, González-Ortiz, Luis Javier, Cid-Hernández, Margarita, Cruz-Serrano, José Antonio, Pacheco-Moisés, Fermín Paul
• Format: Article
• Language: English
• Subjects: Acids; Alzheimer's disease; Antioxidants; Antioxidants - adverse effects; Antioxidants - therapeutic use; Antiparkinson Agents - adverse effects; Antiparkinson Agents - therapeutic use; Biomarkers - blood; Blood platelets; Cell Respiration - drug effects; Clinical trials; Cross-Over Studies; Double-Blind Method; Electron Transport Complex I - metabolism; Enzymes; Humans; Lipid Peroxidation - drug effects; Melatonin; Melatonin - adverse effects; Melatonin - therapeutic use; Metabolites; Mexico; Mitochondria - drug effects; Mitochondria - metabolism; Movement disorders; Neurons; Oxidative stress; Oxidative Stress - drug effects; Parkinson Disease - blood; Parkinson Disease - diagnosis; Parkinson Disease - drug therapy; Parkinson's disease; Plasma; Potassium; Proteins; Software; Statistical analysis; Time Factors; Treatment Outcome
• ISSN: 1942-0900; 1942-0994
• DOI: 10.1155/2021/5577541

Mitochondrial dysfunction and oxidative stress are extensively linked to Parkinson’s disease (PD) pathogenesis. Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects. The aim of this study was to evaluate the effect of melatonin on oxidative stress markers, mitochondrial complex 1 activity, and mitochondrial respiratory control ratio in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial study was conducted in 26 patients who received either 25 mg of melatonin or placebo at noon and 30 min before bedtime for three months. At the end of the trial, in patients who received melatonin, we detected a significant diminution of lipoperoxides, nitric oxide metabolites, and carbonyl groups in plasma samples from PD patients compared with the placebo group. Conversely, catalase activity was increased significantly in comparison with the placebo group. Compared with the placebo group, the melatonin group showed significant increases of mitochondrial complex 1 activity and respiratory control ratio. The fluidity of the membranes was similar in the melatonin group and the placebo group at baseline and after three months of treatment. In conclusion, melatonin administration was effective in reducing the levels of oxidative stress markers and restoring the rate of complex I activity and respiratory control ratio without modifying membrane fluidity. This suggests that melatonin could play a role in the treatment of PD.